^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    1d
    Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=174, Recruiting, Associazione Qol-one | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Promacta (eltrombopag)
    5d
    Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors (clinicaltrials.gov)
    P2, N=40, Recruiting, Changhai Hospital
    New P2 trial
    11d
    Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation: a Single-arm, Open-label, Prospective Clinical Study (clinicaltrials.gov)
    P=N/A, N=45, Recruiting, The General Hospital of Western Theater Command
    New trial
    13d
    rhTPO Dose Escalation vs Eltrombopag Switch in ITP (clinicaltrials.gov)
    P=N/A, N=112, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    Promacta (eltrombopag)
    19d
    Severe aplastic anemia concurrent with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: A case report. (PubMed, Intern Med)
    Treatment prioritized AA with cyclosporine and eltrombopag. Subsequently, the LPL/WM was treated with rituximab monotherapy...Although AA is a diagnosis of exclusion, its coexistence with lymphoma is rare. This case highlights the diagnostic and therapeutic complexity of AA and LPL/WM overlap and suggests that prioritizing the treatment of AA may lead to better outcomes.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Promacta (eltrombopag) • cyclosporine
    21d
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Recruiting | N=39 --> 80
    Enrollment open • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    24d
    Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov)
    P3, N=60, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Rui Lisheng (romiplostim biosimilar)
    27d
    A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Chongqing Peg-Bio Biopharm Co., Ltd.
    New P1/2 trial
    28d
    Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=12, Recruiting, Chongqing Peg-Bio Biopharm Co., Ltd. | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    28d
    A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients (clinicaltrials.gov)
    P1, N=24, Completed, Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting --> Completed
    Trial completion
    1m
    CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2029 --> Oct 2028 | Trial primary completion date: Mar 2029 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag)
    1m
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)